GC
GRAHAM CORP (GHM)·Q4 2025 Earnings Summary
Executive Summary
- Q4 FY25 delivered a broad-based beat: revenue $59.35M (+21% YoY) and GAAP diluted EPS $0.40, with adjusted EPS $0.43; both revenue and EPS exceeded Street consensus for the quarter, a positive near-term catalyst . Consensus: revenue $55.67M*, EPS $0.183* (Primary) versus actual $59.35M and $0.40 GAAP; adjusted EPS $0.43 .*
- Profitability inflected meaningfully: gross margin 27.0% (+110 bps YoY) and adjusted EBITDA $7.65M (12.9% margin), reflecting leverage on higher volume, better execution, and improved pricing .
- Record backlog reached $412.3M with FY25 book-to-bill at 1.1x; orders were $86.9M in Q4, including $50M toward a $136.5M Virginia-class submarine contract, underpinning multi-year visibility .
- FY26 guidance initiated: revenue $225–$235M, gross margin 24.5%–25.5%, adjusted EBITDA $22–$28M; management flagged a $2–$5M tariff headwind and non-recurring FY25 welder grant benefit that will not repeat, tempering margin lift trajectory .
What Went Well and What Went Wrong
-
What Went Well
- Defense strength drove the quarter: Defense sales +$7.7M (+28% YoY), aided by program growth, execution, improved pricing, and milestone timing . “We closed fiscal 2025 with strong momentum… sustained demand across our diversified product portfolio” — CEO Dan Thoren .
- Margin expansion and operating leverage: gross margin to 27.0% (+110 bps YoY) and operating margin to 9.3% (+620 bps YoY) on volume, execution, pricing . CFO: “Both periods reflected leverage on higher volume, better execution, and improved pricing” .
- Backlog and orders visibility: record backlog $412.3M; Q4 orders $86.9M including $50M for Virginia-class long-lead materials; ~45% of backlog expected to convert over 12 months .
-
What Went Wrong
- Tariff headwind into FY26: management estimates $2–$5M tariff impact embedded in FY26 guidance, moderating gross margin versus FY25 .
- Non-recurring grant benefit: FY25 gross profit benefited ~$1.3M from BlueForge welder training grant (~62 bps); no additional grants expected in FY26 .
- Annual orders down YoY due to lumpiness: FY25 orders $231.1M vs $268.4M FY24, reflecting timing in defense programs, though book-to-bill remained 1.1x .
Financial Results
Quarterly comparison (YoY and sequential):
Segment breakdown:
KPIs:
Vs estimates (Q4 FY25):
Values with asterisks retrieved from S&P Global.
Guidance Changes
Notes: FY26 guidance includes estimated tariff impact of $2M–$5M and no recurring welder grant benefit .
Earnings Call Themes & Trends
Management Commentary
- Strategic posture: “We’ve successfully transformed Graham into a well-diversified business… positioned for sustainable growth and improving profitability,” targeting 8%–10% organic revenue growth and low-to-mid teens adjusted EBITDA margins by FY2027 — CEO Dan Thoren .
- Capacity investments: “Automated welding… 30,000 sq ft Batavia facility… cryogenic propellant testing facility in Florida… all completed in calendar year 2025” .
- Backlog visibility: “Record backlog of $412 million… book-to-bill 1.1x for the fifth year in a row” .
- Defense cadence: “This latest [Virginia-class] contract builds upon our successful execution… providing stable, recurring revenue through 2034” .
- CFO margin color: “Gross margin expanded… driven by leverage on higher volume, better execution, improved pricing; FY25 benefited ~$1.3M from the BlueForge grant” .
Selected quotes:
- “We continue to advance projects with an expected 20%+ ROIC… which will drive enhanced margins and create additional revenue opportunities.” — Dan Thoren .
- “We expect revenue in the range of $225M–$235M… maintain strong gross profit margins… adjusted EBITDA $22M–$28M for fiscal 2026.” — CFO Chris Thome .
Q&A Highlights
- Gross margin outlook: Guidance reflects tariff impact and absence of welder grant; no other major mix/labor factors cited; process improvements expected to offset .
- Contract protections: Firm-fixed price with clauses to protect against commodity volatility; ordering high-risk materials early to reduce exposure on multi-year programs .
- Throughput improvements: New radiographic testing equipment and automated welding will simplify complex weld evaluations and improve repeatability; potential cross-over to Energy & Process applications .
- Welder capacity: Batavia welder workforce up ~10% YoY; program well-received; supports defense revenue growth .
- Cryogenic facility: Aggressive commissioning timeline; enough inquiries to “fill up nicely” once operational; differentiates via onsite high-power availability .
- Pricing maturity: Legacy models improved; future value capture as unique test capabilities and R&D deliver differentiated offerings .
Estimates Context
- Q4 FY25 comparison: Revenue $59.35M vs consensus $55.67M*; Primary EPS $0.40 vs consensus $0.183*; adjusted EPS $0.43 (company-reported) .*
- Forward estimates context: Street expects near-term EPS cadence to reflect seasonal and program timing (e.g., Q2–Q4 FY26 EPS consensus mean of ~$0.28*, ~$0.165*, ~$0.368*).*
- Implication: Beat on both revenue and EPS suggests upward bias to near-term estimates, though FY26 tariff headwind and non-recurring FY25 grant imply moderated margin progression versus FY25 .
Values with asterisks retrieved from S&P Global.
Key Takeaways for Investors
- Strong beat and margin expansion with record backlog should support near-term sentiment; defense award timing and Virginia-class long-leads underpin multi-year revenue visibility .
- FY26 guide embeds tariff headwind and no welder grant benefit; near-term gross margin likely flattish-to-slightly down vs FY25, with process improvements and pricing initiatives offset .
- Defense remains the growth engine (59% of Q4 revenue), with clauses mitigating commodity risk and workforce capacity expanding; watch order lumpiness but book-to-bill remains >1x over time .
- Adjusted EBITDA trajectory improving; Barber-Nichols supplemental earn-out ends FY26, potentially adding ~200 bps to adjusted EBITDA margin in FY27 .
- Commercial initiatives (NextGen nozzle, cryogenic testing) provide incremental growth optionality and cross-segment leverage; expect bookings as facilities come online in CY25 .
- Near-term trading: beat vs consensus and record backlog are positive catalysts; monitor tariff developments and backlog conversion (45% next 12 months) for execution signals .
- Medium term: executing stabilize→improve→growth phases, targeting low-to-mid teens adjusted EBITDA margins by FY2027; opportunistic M&A could accelerate product lifecycle expansion .